Cargando…

Study of the erythropoiesis activity of nano-encapsulated forms of erythropoietin

INTRODUCTION: The recombinant human erythropoietin (rhEPO) is used in the treatment of anemia. In order to improve its pharmacokinetic properties, nanoparticles of biodegradable polymers of natural or synthetic origin were used. The aim of this study was to investigate the effect of new nano-encapsu...

Descripción completa

Detalles Bibliográficos
Autores principales: Khasenbekova, Zhanagul, Gulayev, Alexandr, Nechayeva, Elena, Nurgozhin, Talgat, Zhumadilov, Zhaxybay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University Library System, University of Pittsburgh 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960895/
https://www.ncbi.nlm.nih.gov/pubmed/29805869
http://dx.doi.org/10.5195/cajgh.2013.110
_version_ 1783324659168575488
author Khasenbekova, Zhanagul
Gulayev, Alexandr
Nechayeva, Elena
Nurgozhin, Talgat
Zhumadilov, Zhaxybay
author_facet Khasenbekova, Zhanagul
Gulayev, Alexandr
Nechayeva, Elena
Nurgozhin, Talgat
Zhumadilov, Zhaxybay
author_sort Khasenbekova, Zhanagul
collection PubMed
description INTRODUCTION: The recombinant human erythropoietin (rhEPO) is used in the treatment of anemia. In order to improve its pharmacokinetic properties, nanoparticles of biodegradable polymers of natural or synthetic origin were used. The aim of this study was to investigate the effect of new nano-encapsulated forms of recombinant human erythropoietin for oral use on the erythropoiesis in the cyclophosphamide immunosuppression model. MATERIAL AND METHODS: The CHOpE immortalized cells culture (a primary producer of rhEPO “Vector” in Russia) was used. The following biodegradable polymers were chosen: 0.05% and 0.005% carbopol, 0.05% and 0.005% kollidon, and 0.05% and 0.005% pectin. Immunosuppression was obtained by a single dose of i.p. injection of cyclophosphamide (250 mg/kg) in white mice (18–20 g). During the next 5 days, the nano-encapsulated erythropoietin (100 ED/mouse) was administered orally to each mouse. After 5 and 10 days, the cell count of the number of blood reticulocytes and the myelogram of bone marrow were performed. The control group of mice received injections of Eprex. RESULTS: On the 5th day of the experiment, the highest level of reticulocyte was observed in the samples of erythropoietin with kollidon (0.05%) and pectin (0.005%) nanoparticles. On the 10th day, the highest activity was observed in the samples of erythropoietin substance with pectin at 0.05% and 0.005% concentrations. The levels of reticulocytes in these groups reached 13.53% and 14.55%, respectively. The results of the myelogram during immunosuppression showed some activity of erythropoietin in conjunction with both concentrations of pectin when a two-fold increase in the number of erythroblasts was observed on the 5th day. High degrees of erythrokaryocytes in the state of mitosis were observed in the 0.05% pectin samples. Similar results were observed in equivalent groups of control animals on the 10th day of the experiment, which is compatible with the data on Eprex action. CONCLUSION: The erythropoietic activity of nano-encapsulated forms of erythropoietin was observed in the 0.05% and 0.005% pectin samples in the cyclophosphamide immunosuppression model setting.
format Online
Article
Text
id pubmed-5960895
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher University Library System, University of Pittsburgh
record_format MEDLINE/PubMed
spelling pubmed-59608952018-05-25 Study of the erythropoiesis activity of nano-encapsulated forms of erythropoietin Khasenbekova, Zhanagul Gulayev, Alexandr Nechayeva, Elena Nurgozhin, Talgat Zhumadilov, Zhaxybay Cent Asian J Glob Health Articles INTRODUCTION: The recombinant human erythropoietin (rhEPO) is used in the treatment of anemia. In order to improve its pharmacokinetic properties, nanoparticles of biodegradable polymers of natural or synthetic origin were used. The aim of this study was to investigate the effect of new nano-encapsulated forms of recombinant human erythropoietin for oral use on the erythropoiesis in the cyclophosphamide immunosuppression model. MATERIAL AND METHODS: The CHOpE immortalized cells culture (a primary producer of rhEPO “Vector” in Russia) was used. The following biodegradable polymers were chosen: 0.05% and 0.005% carbopol, 0.05% and 0.005% kollidon, and 0.05% and 0.005% pectin. Immunosuppression was obtained by a single dose of i.p. injection of cyclophosphamide (250 mg/kg) in white mice (18–20 g). During the next 5 days, the nano-encapsulated erythropoietin (100 ED/mouse) was administered orally to each mouse. After 5 and 10 days, the cell count of the number of blood reticulocytes and the myelogram of bone marrow were performed. The control group of mice received injections of Eprex. RESULTS: On the 5th day of the experiment, the highest level of reticulocyte was observed in the samples of erythropoietin with kollidon (0.05%) and pectin (0.005%) nanoparticles. On the 10th day, the highest activity was observed in the samples of erythropoietin substance with pectin at 0.05% and 0.005% concentrations. The levels of reticulocytes in these groups reached 13.53% and 14.55%, respectively. The results of the myelogram during immunosuppression showed some activity of erythropoietin in conjunction with both concentrations of pectin when a two-fold increase in the number of erythroblasts was observed on the 5th day. High degrees of erythrokaryocytes in the state of mitosis were observed in the 0.05% pectin samples. Similar results were observed in equivalent groups of control animals on the 10th day of the experiment, which is compatible with the data on Eprex action. CONCLUSION: The erythropoietic activity of nano-encapsulated forms of erythropoietin was observed in the 0.05% and 0.005% pectin samples in the cyclophosphamide immunosuppression model setting. University Library System, University of Pittsburgh 2014-01-24 /pmc/articles/PMC5960895/ /pubmed/29805869 http://dx.doi.org/10.5195/cajgh.2013.110 Text en New articles in this journal are licensed under a Creative Commons Attribution 3.0 License (https://creativecommons.org/licenses/by/3.0/) .
spellingShingle Articles
Khasenbekova, Zhanagul
Gulayev, Alexandr
Nechayeva, Elena
Nurgozhin, Talgat
Zhumadilov, Zhaxybay
Study of the erythropoiesis activity of nano-encapsulated forms of erythropoietin
title Study of the erythropoiesis activity of nano-encapsulated forms of erythropoietin
title_full Study of the erythropoiesis activity of nano-encapsulated forms of erythropoietin
title_fullStr Study of the erythropoiesis activity of nano-encapsulated forms of erythropoietin
title_full_unstemmed Study of the erythropoiesis activity of nano-encapsulated forms of erythropoietin
title_short Study of the erythropoiesis activity of nano-encapsulated forms of erythropoietin
title_sort study of the erythropoiesis activity of nano-encapsulated forms of erythropoietin
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960895/
https://www.ncbi.nlm.nih.gov/pubmed/29805869
http://dx.doi.org/10.5195/cajgh.2013.110
work_keys_str_mv AT khasenbekovazhanagul studyoftheerythropoiesisactivityofnanoencapsulatedformsoferythropoietin
AT gulayevalexandr studyoftheerythropoiesisactivityofnanoencapsulatedformsoferythropoietin
AT nechayevaelena studyoftheerythropoiesisactivityofnanoencapsulatedformsoferythropoietin
AT nurgozhintalgat studyoftheerythropoiesisactivityofnanoencapsulatedformsoferythropoietin
AT zhumadilovzhaxybay studyoftheerythropoiesisactivityofnanoencapsulatedformsoferythropoietin